Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) just unveiled an announcement.
Nanjing Leads Biolabs has reported that its Phase II trial of Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, in first-line advanced biliary tract cancer has successfully moved from the safety run-in stage to the expansion phase after 20 patients showed favorable tolerability and early signs of tumor shrinkage. The multi-center study in China is now enrolling more patients on an accelerated timeline, underscoring the company’s bid to address the limited survival gains seen with current PD-1/PD-L1 plus chemotherapy regimens in this aggressive cancer.
LBL-024 is already in Phase II or registrational studies for non-small cell lung cancer, small cell lung cancer and extrapulmonary neuroendocrine carcinoma, where it has shown promising activity and secured multiple regulatory designations in China, the U.S. and Europe. The advancement of the BTC study broadens the clinical footprint of LBL-024, reinforcing its potential as a broad-spectrum immuno-oncology asset and potentially enhancing Nanjing Leads Biolabs’ competitive standing in the global oncology market if later-stage results confirm its efficacy and safety profile.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$100.50 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative oncology therapies, particularly antibody-based immuno-oncology drugs. Its pipeline includes LBL-024, a PD-L1/4-1BB bispecific antibody positioned for potential first-in-class or best-in-class use across multiple solid tumors with high unmet medical needs.
Average Trading Volume: 738,960
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$17.69B
For detailed information about 9887 stock, go to TipRanks’ Stock Analysis page.